| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
ORIGINAL RESEARCH |
From the Department of Obstetrics and Gynecology, University of Tokushima School of Medicine, Tokushima; Department of Dermatology, Nara Medical University, Nara; Department of Maternal Medicine, Osaka Medical Center, and the Research Institute for Maternal and Child Health, Osaka, Japan.
Address reprint requests to: Kin-ichi Kidoguchi, MD Department of Maternal Medicine, Osaka Medical Center and the Research Institute for Maternal and Child Health 840 Murodo, Izumi Osaka, 594-1101 Japan
Objective: To assess the possibility of preventing cardiac or cutaneous manifestations of neonatal lupus erythematosus or treating the fetus with congenital heart block by administering corticosteroid therapy to the mother.
Methods: Eighty-seven offspring of 40 anti-Ro/SSA-positive mothers, followed up from 1979 to 1996, were evaluated. Autoantibodies against Ro/SSA and La/SSB antigens were detected by immunodiffusion and enzyme-linked immunosorbent assay.
Results: None of 26 neonates whose mothers received corticosteroid maintenance therapy initiated before 16 weeks’ gestation demonstrated congenital heart block, whereas 15 of 61 neonates whose mothers received no corticosteroids during pregnancy or began receiving steroid therapy after 16 weeks’ gestation had congenital heart block. Complete congenital heart block, once developed, did not respond to corticosteroid treatment in utero. Four infants whose mothers received steroid treatment before 16 weeks’ gestation had skin lesions of neonatal lupus erythematosus.
Conclusion: Once established, complete congenital heart block was irreversible and maternal corticosteroid therapy did not effectively prevent cutaneous lupus erythematosus. However, prenatal maintenance therapy with prednisolone or betamethasone given to the mother starting early in pregnancy (before 16 weeks’ gestation) might reduce the risk of developing antibody-mediated congenital heart block in the offspring.
This article has been cited by other articles:
|
|
 |
|
  D. M. Friedman, M. Y. Kim, J. A. Copel, C. Davis, C. K.L. Phoon, J. S. Glickstein, J. P. Buyon, and for the PRIDE Investigators Utility of Cardiac Monitoring in Fetuses at Risk for Congenital Heart Block: The PR Interval and Dexamethasone Evaluation (PRIDE) Prospective Study Circulation, January 29, 2008; 117(4): 485 - 493. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Seferovic, A. D. Ristic, R. Maksimovic, D. S. Simeunovic, G. G. Ristic, G. Radovanovic, D. Seferovic, B. Maisch, and M. Matucci-Cerinic Cardiac arrhythmias and conduction disturbances in autoimmune rheumatic diseases Rheumatology, October 1, 2006; 45(suppl_4): iv39 - iv42. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y Maeno, W Himeno, A Saito, S Hiraishi, O Hirose, M Ikuma, N Inamura, M Kawataki, A Mizukami, M Ota, et al. Clinical course of fetal congenital atrioventricular block in the Japanese population: a multicentre experience Heart, August 1, 2005; 91(8): 1075 - 1079. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V Fesslova, S Mannarino, P Salice, C Boschetto, L Trespidi, B Acaia, F Mosca, R Cimaz, and P L Meroni Neonatal lupus: fetal myocarditis progressing to atrioventricular block in triplets Lupus, October 1, 2003; 12(10): 775 - 778. [Abstract] [PDF]
|
|
|
|
 |
|
 N Costedoat-Chalumeau, Z Amoura, D Le Thi Hong, B Wechsler, D Vauthier, P Ghillani, T Papo, O Fain, L Musset, and J-C Piette Questions about dexamethasone use for the prevention of anti-SSA related congenital heart block Ann Rheum Dis, October 1, 2003; 62(10): 1010 - 1012. [Abstract] [Full Text]
|
|
|
|
|
|
A Brucato, A Jonzon, D Friedman, L D Allan, G Vignati, M Gasparini, J I Stein, S Montella, M Michaelsson, and J Buyon Proposal for a new definition of congenital complete atrioventricular block Lupus, June 1, 2003; 12(6): 427 - 435. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
